Kyle Sramek, MD

Articles by Kyle Sramek, MD

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease

ByMeagan Kubista, MD,Grethel Perez Meek, DO,Kyle Sramek, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

February 20th 2024

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

Latest Updated Articles

Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease
Published: February 20th 2024 | Updated:

Kyle Sramek, MD

Articles by Kyle Sramek, MD

Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease

Latest Updated Articles

Trending on Psychiatric Times

Lithium-Loaded Gold Nanoparticle Nasal Spray to Treat Neuropsychiatric Diseases

Preliminary Report on Dangers of AI Chatbots

The Trial of ChatGPT: What Psychiatrists Need to Know About AI, Suicide, and the Law

6 Helpful Pearls From the International Guidelines for Algorithmic Treatment of Schizophrenia

Suicide: Can Emergency Departments Assist in its Prevention?